Initial Triple Therapy Including Parenteral Treprostinil vs Initial Double Oral Therapy in PAH Group I Patients
A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 110 participants.
Also called NCT06317805
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 110 participants
- Sponsor
- AOP Orphan Pharmaceuticals AG
- Registry
-
NCT06317805 -
2023-504351-26-01
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Argentina, Austria, Czechia, France, Germany, Hungary, Italy, Poland, Portugal, Romania, Spain, Uruguay
- Registry status
- Recruiting
Technical summary
Registry record NCT06317805. Randomized; no masking; primary purpose treatment. Start 2023-12-06 (actual); primary completion 2027-06 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Initial Triple Therapy Including Parenteral Treprostinil vs Initial Double Oral Therapy in PAH Group I Patients
- Acronym
- TripleTRE
- Condition
- Pulmonary Arterial Hypertension
- Intervention (Drug)
- Generic treprostinil sodium + Standard of Care (Double Oral)
- Intervention (Drug)
- Standard of Care - Double Oral
- Lead sponsor
- AOP Orphan Pharmaceuticals AG
- Collaborator
- ANOVA CRO s.r.o.
- Collaborator
- PharmaLex Belgium
- Collaborator
- Aixial s.r.o.
- Collaborator
- GCP-Service International Ltd. & Co. KG
Record details
- Record id
cardio:ct-nct06317805- Content hash
73d3fb4712de185d62e8cfedefe3946277ed654ae8a09d5cd2b101b48e38cee1